GET DAILY SIGNALSCytoSorbents (CTSO) Reaches Operating Cash Flow Breakeven in Q3 Despite Modest Revenue Miss
Key Takeaways
- Third-quarter revenue rose 3% year over year to $9.7 million, led by a 16% increase in distributor and strategic partner sales.
- Product gross margin climbed to 75%, up from 73% in the prior quarter and 70% a year ago, reflecting manufacturing and sourcing efficiencies.
- The company achieved its stated goal of operating cash flow breakeven, generating roughly $43,000 in positive operating cash flow excluding restructuring-related payments.
- Adjusted EBITDA loss narrowed 86% to about $0.3 million, while the operating loss improved 59% to $1.2 million.
- Adjusted net loss per share of $0.48 beat consensus estimates, although revenue of $9.73 million came in slightly below expectations.
- Net loss improved 42% to $1.8 million, or $0.58 per share, reflecting the 1-for-20 reverse stock split completed in September 2026.
Earnings Context and Why It Matters
CytoSorbents Corporation, a developer of blood-purification technologies for critical care and cardiac surgery, has spent much of the past year rebuilding its cost structure. A workforce and cost-reduction program, lower operating expenses, and tighter working-capital management have all aimed at one goal: reaching operating cash flow breakeven in the second half of 2026. This quarter tested whether that turnaround was real, at a time when the company is also working toward U.S. regulatory approval of its DrugSorb-ATR device. For investors, the report matters because it shows whether management can fund the business without repeatedly tapping capital markets, even as its German commercial operations remain under pressure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, CytoSorbents reported revenue of $9.7 million, up 3% from $9.5 million a year earlier. Growth was driven by a 16% increase in distributor and strategic partner sales, while direct sales outside Germany rose 4%. These gains were partially offset by a 20% decline in Germany, where a smaller, restructured sales force reduced territory coverage.
Product gross margin reached 75%, improving from 73% in the second quarter and 70% a year ago. Total operating expenses fell 11% to $8.5 million, helping shrink the operating loss by 59% to $1.2 million. Net loss improved 42% to $1.8 million, or $0.58 per share. On an adjusted basis, net loss was $1.5 million, or $0.48 per share, and adjusted EBITDA loss narrowed 86% to about $0.3 million.
Compared with Wall Street expectations, adjusted earnings per share of a $0.48 loss beat the consensus estimate of a $0.80 loss, while revenue of $9.73 million slightly missed the roughly $10.1 million consensus. Crucially, the company generated approximately $43,000 in positive operating cash flow excluding restructuring payments, achieving its operating cash flow breakeven target. Total cash and restricted cash stood at about $5.7 million at quarter-end.
Market Reaction and Investor Sentiment
The market's response to the quarter reflected a mixed scorecard: a meaningful earnings beat and a landmark cash-flow milestone were tempered by a modest revenue shortfall. Shares of CTSO have been volatile over the past year, pressured by a reverse stock split, Nasdaq minimum-bid-price compliance efforts, and persistent losses. Achieving operating cash flow breakeven removes one of the most persistent concerns for shareholders, but the revenue miss in Germany and ongoing regulatory uncertainty around DrugSorb-ATR remain key watchpoints for sentiment heading into year-end.
Forward Outlook and Key Factors to Monitor
Management's immediate priority is sustaining operating cash flow at or near breakeven while selectively investing to reignite sales growth. Germany, which still represents about 24% of quarterly revenue, is a central focus. The company has begun adding sales representatives and brought in new senior sales leadership, with plans to continue hiring through early 2027. Investors should watch whether these additions translate into a stabilization and eventual recovery in the German market.
On the regulatory front, the company is advancing a new De Novo submission to the U.S. Food and Drug Administration (FDA) for DrugSorb-ATR, now expected in early 2027, supported by real-world data showing a 37% relative reduction in severe bleeding among urgent cardiac surgery patients. A separate De Novo pathway for direct oral anticoagulants is also in discussion. These regulatory milestones are significant longer-term catalysts, but timing remains subject to FDA alignment.
Other factors to monitor include gross margin durability in the mid-70% range, working-capital discipline, and any fluctuations in quarterly cash flow tied to revenue timing. While the breakeven milestone strengthens the company's financial footing, the path to sustainable profitability still depends on restoring growth in core markets and advancing its pipeline without additional significant capital needs.
Streamlining Research with Tickeron Tools
In my own workflow, Tickeron's AI Screener has proven useful for quickly filtering stocks by fundamentals, patterns, and performance metrics. It helps surface relevant comparables and validate ideas without hours of manual effort, making the screening process more efficient overall.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CTSO turns positive, indicating new upward trend
CTSO saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned positive. In 84 of the 107 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CTSO just turned positive on October 08, 2026. Looking at past instances where CTSO's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +26.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTSO advanced for three days, in 188 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for CTSO moved below the 200-day moving average on November 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTSO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CTSO broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTSO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CTSO's P/B Ratio (-20.140) is slightly lower than the industry average of (4.142). P/E Ratio (-0.828) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.483) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CTSO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTSO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of products to support healthcare professionals in the treatment of complex medical conditions
Industry MedicalNursingServices
Advertisement